Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 3/20 | 0.73 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.73 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.66 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.56 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.53 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 4/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | NPC1 | O15118 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | PARP1 | P09874 | 1/20 | 0.49 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL70173 | 0.90 | CYP4F2 (0.83) | CYP4F2CYP4A11LOXL2SLC7A5HIF1A | |
| SCHEMBL184267 | 0.86 | CYP4F2 (0.60) | CYP4F2CYP4A11LOXL2SLC7A5HIF1A | |
| SCHEMBL46931 | 0.85 | CYP4A11 (1.00) | CYP4F2CYP4A11LOXL2SLC7A5HIF1A | |
| SCHEMBL1926802 | 0.85 | CYP4F2 (0.76) | CYP4F2CYP4A11LOXL2SLC7A5HIF1A | |
| SCHEMBL1696378 | 0.85 | CYP4F2 (0.76) | CYP4F2CYP4A11LOXL2SLC7A5HIF1A | |
| SCHEMBL25464938 | 0.85 | LOXL2 (0.68) | CYP4F2CYP4A11LOXL2SLC7A5HIF1A | |
| SCHEMBL10609527 | 0.85 | CYP4F2 (0.76) | CYP4F2CYP4A11LOXL2SLC7A5HIF1A | |
| SCHEMBL30417629 | 0.85 | LOXL2 (0.68) | CYP4F2CYP4A11LOXL2SLC7A5HIF1A | |
| SCHEMBL3012713 | 0.83 | LOXL2 (0.76) | CYP4F2CYP4A11LOXL2SLC7A5HIF1A | |
| SCHEMBL5544436 | 0.83 | CYP4F2 (0.73) | CYP4F2CYP4A11LOXL2SLC7A5HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060270649-A1 | AZETIDINE DERIVATIVES, THEIR PREPARATION AND MEDICAMENTS CONTAINING THEM | AVENTIS PHARMA S.A. (FR) | 2006-11-30 | — | — | US | disclosed |
| US-6858603-B2 | Acetindine derivatives, their preparation and medicaments containing them | AVENTIS PHARMA S.A. (FR) | 2005-02-22 | — | — | US | disclosed |
| US-20040235816-A1 | Azetidine derivatives, their preparation and medicaments containing them | AVENTIS PHARMA S.A. (FR) | 2004-11-25 | — | — | US | disclosed |
| US-20030162808-A1 | Acetindine derivatives, their preparation and medicaments containing them | AVENTIS PHARMA S.A. (FR) | 2003-08-28 | — | — | US | disclosed |
| US-6518264-B2 | For treatment/prevention of psychoses, other brain disorders, and cardiovascular disorders | AVENTIS PHARMA S.A. (FR) | 2003-02-11 | — | — | US | disclosed |
| US-20020035102-A1 | Azetidine derivatives, their preparation and medicaments containing them | AVENTIS PHARMA S.A. (FR) | 2002-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235816-A1 | Azetidine derivatives, their preparation and medicaments containing them | AZI2, ADRA2A, ADRA2C | CYP4F2 359/4885CYP4A11 126/4885LOXL2 2193/4885 |
| US-20060270649-A1 | AZETIDINE DERIVATIVES, THEIR PREPARATION AND MEDICAMENTS CONTAINING THEM | AZI2, QDPR, ADRA2A | CYP4F2 416/4885CYP4A11 160/4885LOXL2 2154/4885 |
| US-20020035102-A1 | Azetidine derivatives, their preparation and medicaments containing them | CYP11B2, AZI2, CYP2C19 | CYP4F2 148/4885CYP4A11 41/4885LOXL2 2646/4885 |
| US-20030162808-A1 | Acetindine derivatives, their preparation and medicaments containing them | ADRA1D, ADRB2, AZI2 | CYP4F2 245/4885CYP4A11 199/4885LOXL2 3540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.